Mamun Al‐Mahtab, Michel Bazinet, Andrew Vaillant
UNLABELLED: Previous in vivo studies have suggested that nucleic acid polymers (NAPs) may reduce circulating levels of HBsAg in the blood by blocking its release from infected hepatocytes and that this effect may have clinical benefit. NAP treatment, was evaluated in two clinical studies in patients...
Louis Jansen, Andrew Vaillant, F. Stelma, Neeltje A. Kootstra et al.
Zainab Usman, Hrvoje Mijočević, Hadi Karimzadeh, Martin Däumer et al.
Chronic HBV infection results in various clinical manifestations due to different levels of immune response. In recent years, hepatitis B treatment has improved by long-term administration of nucleos(t)ide analogues (NUCs) and peg-interferon. Nucleic acid polymers (NAPs; REP 2139-Ca and REP 2139-Mg)...
M. Al-Mahtab, Michel Bazinet, Andrew Vaillant
M. Al-Mahtab, Michel Bazinet, Andrew Vaillant
Hrvoje Mijočević, Hadi Karimzadeh, Judith Seebach, Zainab Usman et al.
The treatment of patients suffering from HBeAg-positive chronic hepatitis B with REP 2139-Ca resulted in potent reductions in HBsAg and HBV DNA, seroconversion to anti-HBs and the establishment of functional control of infection. In this cohort of 12 patients, we investigated whether differences bet...
Ed Susman
FigureVIENNA, Austria—An investigative agent appears to rapidly and dramatically reduce both hepatitis B virus surface antigen and hepatitis D virus infection in co-infected individuals, researchers reported here at the International Liver Congress, sponsored by the European Association for the Stud...
F. Stelma, Andrew Vaillant, Louis Jansen, Marjan J. Sinnige et al.
Mamun Al‐Mahtab, Michel Bazinet, Andrew Vaillant
Hrvoje Mijočević, Hadi Karimzadeh, Judith Seebach, Zainab Usman et al.
Completed and ongoing clinical trials in hepatitis B virus (HBV) mono-infection and chronic HBV/hepatitis delta (HDV) co-infection have demonstrated that therapy with the lead clinical nucleic acid polymer (NAP) candidate, REP 2139, results in multilog reduction or loss of HBsAg in the blood associa...
Zainab Usman, Hrvoje Mijočević, Hadi Karimzadeh, M. Al-Mahtab et al.
Nucleic acid polymers (NAPs) clear HBsAg from the blood by blocking its release from infected hepatocytes of patients with chronic Hepatitis B. In the REP 102 protocol (NCT02646189) monotherapy with the NAP REP 2139 achieved 2 – 7 log reductions of serum HBsAg accompanied by 3 – 9 log reductions in ...